Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02393209 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02393209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 3, 2015
Completion date
January 20, 2017
Enrollment
14 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer